ERGOSTAT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ergostat, and what generic alternatives are available?
Ergostat is a drug marketed by Watson Labs Inc and is included in one NDA.
The generic ingredient in ERGOSTAT is ergotamine tartrate. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ergotamine tartrate profile page.
Summary for ERGOSTAT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 15 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,981 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ERGOSTAT at DailyMed |
Recent Clinical Trials for ERGOSTAT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stanford University | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for ERGOSTAT
US Patents and Regulatory Information for ERGOSTAT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs Inc | ERGOSTAT | ergotamine tartrate | TABLET;SUBLINGUAL | 088337-001 | Jun 8, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
